Sector News

Baxter pads biopharma unit with pre-spinoff oncology buy

May 13, 2015
Life sciences
As Baxter gears up to spin off its biopharma unit into new company Baxalta, it wants to make sure the new pharma has enough revenue to rely on. And to do that, it’s bulking up.
 
The Illinois company has agreed to purchase leukemia treatment Oncaspar from Italy’s Sigma-Tau Finanziaria for $900 million, it said Tuesday. The therapy–part of a first-line chemo regimen to treat acute lymphoblastic leukemia (ALL)–will play a key role in Baxalta’s oncology division, Baxter said, with $100 million in annual sales from countries including the U.S., Germany and Poland.
 
“The acquisition provides an immediate commercial footprint in the United States and Europe with a heritage of expertise in treating this challenging disease,” David Meek, Baxter BioScience’s head of oncology, said in a statement.
 
And Baxter won’t stop there. It plans to investigate Oncaspar for potential new indications, it said, both in ALL and other cancers–including acute myeloid leukemia.
 
Baxter’s not the only company shelling out to get in on the booming oncology market. In March, AbbVie agreed to fork over $21 billion for Pharmacyclics, which markets blood cancer drug Imbruvica with partner Johnson & Johnson. And a few days prior, Novartis  closed its $16 billion pickup of GlaxoSmithKline’s cancer assets.
 
For Baxter, whose biopharma business relies heavily on its hemophilia drugs, cancer meds will be an important sales source. The company thinks the oncology sector represents $10 billion in total market potential for its pipeline assets, it said–and with two new, long-lasting Biogen challengers to its leading hemophilia products out there, that’s revenue Baxalta could use.
 
By Carly Helfand
 

1 response to “Baxter pads biopharma unit with pre-spinoff oncology buy

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend